Telmisartan is an angiotensin II receptor blocker indicated for hypertension and cardiovascular risk reduction. We supply it to US manufacturers of tablets and fixed-dose combinations.
Data from PubChem (CID 65999) and FDA’s substance registry
CAS number
144701-48-4
Molecular formula
C33H30N4O2
Molecular weight
514.6g/mol
FDA UNII
IUPAC name
2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
InChIKey
RMMXLENWKUUMAY-UHFFFAOYSA-N
- Appearance
- White to slightly yellowish solid.
- Solubility
- Practically insoluble in water and across pH 3 to 9. Sparingly soluble in strong acid, except hydrochloric acid, and soluble in strong base.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Unlike losartan and valsartan it has no tetrazole ring, so the azide chemistry behind the 2018 sartan recalls is not part of its route. Because it is practically insoluble at intestinal pH, particle size matters to dissolution.
On the US market
- Reference product
- MicardisNDA 020850
- Approved ANDAs
- 15 with a marketed product
- Approved forms and strengths
- Tablet 20 mg, 40 mg, 80 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com